0000000000324938

AUTHOR

Christian I. Surcel

showing 3 related works from this author

A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strateg…

2020

Abstract Context The role of immune checkpoint inhibition (ICI) in the treatment of prostate cancer (PC) still remains elusive. It has been proposed that combination of ICI with other molecules increases the efficacy of immunotherapy in PC. Objective To systematically review the literature to assess the potential role of ICI in combination with additional therapies for the management of metastatic castration-resistant PC (mCRPC). Evidence acquisition A systematic review using Medline and scientific meeting records was carried out in September 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. Ongoing trials of immunotherapy with standard mCRP…

OncologyMalemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyMEDLINEContext (language use)Androgen deprivation therapy03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingCombination therapies; Immunotherapy; Metastatic castration-resistant prostate cancerImmune Checkpoint Inhibitorsbusiness.industryAndrogen AntagonistsImmunotherapymedicine.diseaseImmune checkpointMetastatic castration-resistant prostate cancerClinical trialRadiation therapyProstatic Neoplasms Castration-ResistantOncology030220 oncology & carcinogenesisSurgeryCombination therapiesImmunotherapybusinessEuropean urology oncology
researchProduct

Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment

2019

Background: Active surveillance (AS) has been increasingly proposed as the preferential initial management strategy for low-risk prostate cancer (PC), while in high-risk PC the indication for surgery has widened. Objective: To evaluate the development of risk group distribution of patients undergoing radical prostatectomy (RP). Design, setting, and participants: Retrospective database review of combined RP databases (2000-2015) of four large European centers (Créteil, Paris; San Rafaele, Milan; Martini Klinik, Hamburg; NKI, AvL, Amsterdam). Outcome measurements and statistical analysis: Clinical and pathological characteristics per year of surgery. Eligibility for AS was defined according …

Malemedicine.medical_specialtymedicine.medical_treatmentUrology030232 urology & nephrologyRisk classificationDiseaseActive surveillanceRisk AssessmentTreatment trend03 medical and health sciencesProstate cancer0302 clinical medicineRisk groupsInternal medicineHumansMedicineDistribution (pharmacology)Watchful WaitingPathologicalRetrospective StudiesProstatectomyProstate cancerbusiness.industryProstatectomyProstatic NeoplasmsCancerProstate-Specific Antigenmedicine.diseaseTailored treatmentRadical prostatectomySurgeryEurope030220 oncology & carcinogenesisNeoplasm Gradingbusiness
researchProduct

Hereditary prostate cancer – Primetime for genetic testing?

2019

Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5-15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the cli…

0301 basic medicineMaleGenetic testingDNA Copy Number VariationsGenome-wide association studySingle-nucleotide polymorphismDiseaseBioinformaticsPolymorphism Single Nucleotide03 medical and health sciencesProstate cancer0302 clinical medicineGermline mutationMedicineHumansRadiology Nuclear Medicine and imagingGenetic Predisposition to DiseaseCopy-number variationGenetic TestingPrecision MedicineGenetic testingBRCA2 ProteinHomeodomain ProteinsClinical Trials as TopicProstate cancermedicine.diagnostic_testbusiness.industryBRCA1 ProteinCancerProstatic NeoplasmsPrecision oncologyGeneral Medicinemedicine.diseaseCheckpoint Kinase 2030104 developmental biologyHereditaryOncology030220 oncology & carcinogenesisMutationbusiness
researchProduct